<DOC>
	<DOCNO>NCT03055221</DOCNO>
	<brief_summary>This open-label extension Study RIV-PH-402 , TRUST-1 : Treprostinil Untreated Symptomatic Pulmonary Arterial Hypertension ( PAH ) Trial . Subjects complete Study RIV-PH-402 eligible enroll .</brief_summary>
	<brief_title>TRUST-2 : Safety Efficacy Intravenous RemodulinÂ® Patients India With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subjects enrol complete Study RIVPH402 ( TRUST1 ) Subjects unblinded potential rescue therapy Study RIVPH402 find allocate Remodulin treatment group eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Remodulin</keyword>
	<keyword>6-Minute Walk Test</keyword>
</DOC>